HRQOL AND HEALTH UTILITY IMPACT ON PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN US AND EUROPE- A SYSTEMATIC LITERATURE REVIEW

Author(s)

Ahuja A1, Attri S2, Kamra S3, Kalra M2, Marwaha IS2
1PAREXEL Access Consulting, Chandigarh, India, 2Paraxel International, Chandigarh, India, 3Parexel International, Chandigarh, India

OBJECTIVES: This systematic literature review (SLR) aimed to identify health related quality of life (HRQoL) and health utility parameters among newly diagnosed multiple myeloma (MM) patients. METHODS: Systematic searches were conducted in literature databases including Embase® and MEDLINE® from Januray 2005 to June 2015. English language studies, regardless of design and intervention were included. Each study was reviewed by two independent reviewers; any disagreements were resolved by a third reviewer. RESULTS: Out of the 680 citations retrieved from literature databases, 12 were included in the review. The included studies were observational (n=6), randomised controlled trials (n=5),  or cost-effectiveness analysis (n=1). Of 12 included studies, seven were conducted in US, three in Europe, and one each in Europe/US and Europe/other countries. Most commonly reported HRQoL scales were EORTC OLQ-C30, QLQ-MY20, and FACT-MM; while, health utility was estimted by EQ-5D. The HRQoL was significantly impaired in patients with MM compared to normative patients in terms of EORTC QLQ-C30 (p<0.01); with QoL, dyspnoea, physical functioning, role functioning, and social functoning subscales being the most affected. Further, disease progression was associated with a worsening in HRQOL scores (p<0.001). Impaired HRQoL was reported in patients with MM because of disease related symptoms like bone pain and fatigue. Mean pain scores worsened with more severe disease stage (p<0.05). Impaired HRQoL due to higher fatigue and pain scores was associated with shorter overall survival. Males had better HRQoL scores compared to females (p=0.04) and blacks had better HRQoL scores compared to non-blacks (p=0.03). Additionally, impaired health-related utility values were reported in patients with MM as sugested by a mean EQ-5D score of less than 0.5. CONCLUSIONS: Disease severity, gender, and race are few of the parameters that are  associated with deterioration of HRQoL in patients with newly-diagnosed MM. Delaying disease progression could possibly help to improve HRQoL.

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PCN217

Topic

Patient-Centered Research

Topic Subcategory

Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×